Latest GLOBAL X S&P BIOTECH ETF (ASX:CUR) News

Page 1

Page 1 of 1

OFX plunge leads a week of takeover doubt, legal risk and fund warnings

Finance Wrap - Week 39 (21 Sept -> 25 Sept) 2026

Takeover uncertainty, legal risks and fund closures drove the biggest share moves this week.
Dividend growth and stronger fund returns offered support, but several reports carried clear warnings about future results.

Logan Eniac

26 Sept 2026

CURE’s biotech rebound delivers a AUD22.6m profit

Global X biotech ETF swings to AUD22.6m profit as assets climb

Global X S&P Biotech ETF (ASX:CURE) reported a AUD22.601 million profit for the year to 30 June 2026, reversing the prior year’s AUD2.863 million loss. The turnaround was driven overwhelmingly by gains in listed biotech securities and foreign exchange, rather than recurring income.

Claire Turing

25 Sept 2026